title: The efficacy of bimatoprost 0.03% monotherapy in patients previously using topical beta-blocker monotherapy for the treatment of glaucoma or ocular hypertension.
abstract: In an open-label 12-week study, the safety and efficacy of bimatoprost 0.03% was evaluated in 55 patients with open-angle glaucoma or ocular hypertension inadequately controlled by topical beta-blocker monotherapy. Patients discontinued their topical beta-blocker therapy at the baseline visit and began bimatoprost monotherapy that evening. Study visits were at 6 and 12 weeks postbaseline. Bimatoprost reduced intraocular pressure (IOP) 4.5 mm Hg (21.5%; P < .001) from baseline at week 6 and 4.2 mm Hg (19.6%; P < .001) at week 12. Patients were more likely to achieve low target pressures with bimatoprost than with topical beta-blockers. Conjunctival hyperemia was the most commonly reported adverse event. The findings from this study indicate bimatoprost monotherapy provides a substantially greater IOP reduction than topical beta-blocker therapy and allows more patients to achieve a low target pressure. Bimatoprost is an effective alternative to topical beta-blockers for the treatment of glaucoma and ocular hypertension.
authors.affiliation: Arbor Center for Eye Care, 2640 183rd Street, Homewood, IL 60430, USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Quinones
authors.forename: Melissa L
authors.initials: ML
authors.lastname: Earl
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000368:Aged; D000577:Amides; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000069580:Bimatoprost; D003008:Cloprostenol / Q000031:analogs & derivatives; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008055:Lipids / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions
chemical_list: D000319:Adrenergic beta-Antagonists; D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D009883:Ophthalmic Solutions; D003008:Cloprostenol; D000069580:Bimatoprost